An experimental drug has reduced gluten-triggered intestinal damage in people with celiac disease in an early clinical trial.
The drug, called TEV '408, blocks an immune signal known as IL-15, which is believed to play an important role in the damaging immune reaction caused by gluten.
Teva announced the Phase 2a results on September 2, 2026. The study involved 50 adults with celiac disease and compared the drug with placebo.
The findings are encouraging, but they are still early.
Why is celiac disease difficult to treat?
Celiac disease is an autoimmune condition.
When someone with celiac disease eats gluten, the immune system reacts abnormally and damages the lining of the small intestine.
The small intestine normally has millions of tiny finger-like structures called villi, which help absorb nutrients.
In celiac disease, these villi can become damaged and shortened.
At present, the main treatment is a strict gluten-free diet.
That works well for many people, but avoiding gluten completely can be difficult because of accidental exposure and food contamination.
What is TEV '408?
TEV '408 is an experimental antibody treatment.
Instead of removing gluten from food, it tries to block part of the immune reaction that causes intestinal injury.
The treatment targets IL-15, a chemical signal involved in inflammation in celiac disease.
What did the study do?
The study included 50 adults with celiac disease who were already following a gluten-free diet.
Participants received either a single injection of TEV '408 or placebo.
Two weeks later, they began eating a controlled amount of gluten every day for six weeks.
Researchers then compared intestinal biopsy samples and recorded gastrointestinal symptoms.
What did researchers find?
People who received TEV '408 showed less microscopic damage to the lining of the small intestine than those who received placebo.
They also had much less increase in inflammatory immune cells in the intestine and reported fewer gastrointestinal symptoms.
The company said no new safety problem had emerged during the study so far.
Why is this interesting?
The study suggests that blocking the IL-15 pathway may reduce the biological damage caused by gluten.
That could eventually lead to treatments that do more than simply help people avoid gluten.
For example, future therapies might help protect against accidental gluten exposure or reduce continuing intestinal inflammation.
But the present study does not prove that yet.
What are the limitations?
There are several important ones.
The study was small, involving only 50 people.
It was also a Phase 2a trial, which is still an early stage of drug development.
The participants were deliberately exposed to gluten under controlled study conditions, which does not perfectly reflect everyday life.
Most importantly, the available results are currently topline results announced by the manufacturer, not a full peer-reviewed scientific publication.
Researchers still need to establish whether the benefit lasts, how often the drug would need to be given, whether it remains safe over longer periods, and whether it improves real-world outcomes.
Does this mean people with celiac disease can eat gluten?
No.
TEV '408 is still experimental.
People with celiac disease should continue following their recommended gluten-free diet.
The importance of this study is that it gives researchers encouraging early evidence that another biological treatment approach may be possible.
Evidence so far
Evidence strength: Promising but early
The trial was randomized and placebo-controlled, which strengthens the findings.
However, it involved only 50 adults and the currently available results are preliminary company-reported findings.
